CANVAS Trial Results: Better For Janssen, Lilly Or the SGLT2 Class?

Janssen's Invokana reduced cardiovascular events in CANVAS on par with the MACE reduction in Lilly's and Boehringer's EMPA-REG trial for competing SGLT2 inhibitor Jardiance, but the CV benefit comes with a doubling of amputation risk versus placebo.